The MART-1 / Melan-A Antibody from GeneBioSolution is a high-quality antibody validated for immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded (FFPE) tissues). MART-1 (Melanoma Antigen Recognized by T-cells 1), also known as Melan-A, is a melanocyte differentiation antigen expressed in normal melanocytes and the majority of melanomas. This antibody provides sensitive and specific cytoplasmic staining of melanocytic cells, with minimal background. It is widely used in diagnostic pathology for the identification of primary and metastatic melanomas, as well as other melanocytic lesions. MART-1 / Melan-A immunostaining is highly valuable in differentiating melanoma from non-melanocytic tumors, especially when used in an IHC panel with HMB-45 and SOX10. It is also applied in research exploring melanocyte biology, melanoma progression, and immunotherapy development, since MART-1/Melan-A is a recognized target of cytotoxic T-cell responses in cancer immunology. All GeneBioSolution antibodies undergo rigorous validation and quality control, ensuring lot-to-lot consistency, reproducible staining, and compatibility with both manual and automated IHC platforms.
Mouse
M2-7C10
Mouse IgG2b, Kappa
Human. Clone M2-7C10 does not react with mouse or rat.
Metastatic melanoma in lymph nodes.
The clone M2-7C10 MART-1 antibody labels melanomas and other tumors showing melanocyte differentiation.
Recombinant human MART-1 protein was used to generate the MART-1 antibody.
Cytoplasmic.
At Genebiosolution, our commitment lies in crafting cutting-edge solutions for researchers, clinicians, and diagnostic laboratories seeking excellence in immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). With a focus on quality, reliability, and accuracy, our products empower advancements in molecular diagnostics and research methodologies.
